Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
Clinical Infectious Diseases · 25.02.2026 · 82 (2) · e262-e274
DOI: 10.1093/cid/ciaf565 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 10.10.2025. Verfasst von Sergio Serrano-Villar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, and Universidad de Alcalá, Madrid, Spain. Hauptthemen laut MEDLINE: HIV Infections, Heterocyclic Compounds, 3-Ring, Lamivudine, Anti-HIV Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Dual antiretroviral therapy (ART) with dolutegravir/lamivudine (DTG/3TC) is widely used in virologically suppressed individuals. However, data remain limited on potential differential effects of ART regimens on mid-term systemic inflammation and metabolic health. We evaluated whether switching from DTG/3TC to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) modifies systemic inflammation or metabolic parameters.
Methods
INSTINCT was a phase IV, multicenter, open-label, randomized trial enrolling adults with HIV-1 on stable DTG/3TC and sustained viral suppression. Participants were randomized (1:1) to continue DTG/3TC or switch to BIC/FTC/TAF and followed for 96 weeks. Plasma biomarkers (sCD14, IL-6, sCD163, hsCRP, D-dimer, and kynurenine/tryptophan ratio) were measured at baseline, week 48, and week 96. Secondary outcomes included CD4⁺ and CD4/CD8 ratio, virological suppression, weight, lipid profile, and renal function. Longitudinal changes were analyzed using linear mixed-effects models.
Results
A total of 141 participants were randomized. Over 96 weeks, no significant between-group differences were observed in inflammatory biomarkers. CD4⁺ T-cell counts and CD4/CD8 ratio remained stable and comparable across arms. Weight changes were modest and similar; the proportion with ≥5% weight gain did not differ. No relevant differences were found in lipids, glucose, or eGFR. Virological suppression was maintained in >95% of participants. Adverse events were mild and balanced between groups.
Conclusions
In virologically suppressed individuals, maintaining DTG/3TC or switching to BIC/FTC/TAF demonstrated equivalent profiles with respect to systemic inflammation, metabolic outcomes, and immunologic markers over 96 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, and Universidad de Alcalá, Madrid, Spain.
- CIBER de Enfermedades Infecciosas, Madrid, Spain.
- Department of Medicine, Universidad Antonio de Nebrija, Madrid, Spain.
- Department of Infectious Diseases, Hospital Universitario de Bellvitge, Barcelona, Spain.
- Department of Internal Medicine, Hospital Universitario Príncipe de Asturias, Madrid, Spain.
- Division of Infectious Diseases, Health Research Institute-Fundación Jiménez Díaz University Hospital and Universidad Autónoma de Madrid(IIS-FJD, UAM), Madrid, Spain.
ORCID-Profile: Sergio Serrano-Villar, Juan Tiraboschi, Alfonso Cabello-Úbeda, Luis López-Cortés, Carmen Busca, Miguel Torralba, Carmen Hidalgo-Tenorio, Ana Del Amo-de Palacios, Enrique Bernal, Jesús Troya, José Ramón Blanco, Santiago Moreno
Zitieren
APA
Serrano-Villar, S., Martín-Pedraza, L., Tiraboschi, J., Novella, M., Cabello-Úbeda, A., López-Cortés, L., Busca, C., Torralba, M., Crusells, M. J., Hidalgo-Tenorio, C., Estrada, V., Del Amo-de Palacios, A., Díaz de Santiago, A., Fons-Contreras, M., Santos, J., Bernal, E., Montero-Alonso, M., Troya, J., Blanco, J. R., …, & Moreno, S. (2026). Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study). Clinical Infectious Diseases, 82(2), e262-e274. https://doi.org/10.1093/cid/ciaf565
Vancouver
Serrano-Villar S, Martín-Pedraza L, Tiraboschi J, Novella M, Cabello-Úbeda A, López-Cortés L, et al. Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study). Clinical Infectious Diseases. 2026;82(2):e262-e274. doi:10.1093/cid/ciaf565
BibTeX
@article{SerranoVillar2026,
author = {Serrano-Villar, Sergio and Martín-Pedraza, Laura and Tiraboschi, Juan and Novella, María and Cabello-Úbeda, Alfonso and López-Cortés, Luis and Busca, Carmen and Torralba, Miguel and Crusells, María José and Hidalgo-Tenorio, Carmen and Estrada, Vicente and Del Amo-de Palacios, Ana and Díaz de Santiago, Alberto and Fons-Contreras, María and Santos, Jesús and Bernal, Enrique and Montero-Alonso, Marta and Troya, Jesús and Blanco, José Ramón and Burgos, Joaquín and de Miguel, Marta and Moreno, Santiago},
title = {Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {2},
pages = {e262--e274},
doi = {10.1093/cid/ciaf565}
}
EUVIMED